Toxicity and off-target effects are major challenges in the development of antibody-drug conjugates, often limiting their therapeutic potential. CROs play a critical role in addressing these challenges by offering comprehensive preclinical services, including in vitro and in vivo safety profiling, biomarker analysis, and pharmacokinetic testing. Through advanced technologies and expertise, CROs help identify potential toxicities early in the development process, enabling informed decisions about linker design, payload selection, and dosing strategies. This session will explore how CROs contribute to reducing systemic toxicity and enhancing the safety profiles of ADCs, ensuring more effective and safer therapies for patients.